HR Execs on the Move

Phylagen

www.phylagen.com

 
Phylagen is a venture-backed microbiome data analytics company that harnesses the vast, unseen world of microbes to improve business performance and make our lives better.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Jessica Green
Co Founder Profile

Similar Companies

Solarea Bio

Solarea Bio is a preclinical-stage biotechnology company in Cambridge, MA developing new microbiome-based solutions to some of the world`s largest health problems.

EcoArray

EcoArray is a Gainesville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Purdue Pharma

Purdue Pharma L.P. is a privately held pharmaceutical company founded by physicians more than 60 years ago. We are committed to advancing the care of patients with innovative, quality products that make a positive impact on healthcare — and on lives. Purdue Pharma is part of a global network of independent associated companies that is known for pioneering research in chronic pain and opioids with abuse deterrent properties. The Company is engaged in the research, development, production, and marketing of prescription medicines and over-the-counter healthcare products. We are pursuing a promising pipeline of new medications through internal research & development and strategic industry partnerships. At Purdue, we embrace our mission to find, develop, and introduce innovative medicines that meet the evolving needs of healthcare professionals, patients and caregivers.

Aradigm Corporation

Aradigm Corporation is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Medicinova

MediciNova, Inc., a development stage biopharmaceutical company, focuses on acquiring and developing small molecule therapeutics for the treatment of serious diseases for the United States market. The company’s principal product candidates include MN-166, an ibudilast-based drug candidate, which is in Phase I and Phase II clinical trials for the treatment of drug dependence and pain; and MN-221, a ß2 -adrenergic receptor agonist that has completed Phase II clinical trials for the treatment of acute exacerbations of asthma. It also has other product candidates in the clinical development for the treatment of acute exacerbations of asthma, multiple sclerosis and other central nervous system disorders, bronchial asthma, interstitial cystitis, solid tumor cancers, generalized anxiety disorders/insomnia, preterm labor, urinary incontinence, and thrombotic disorders. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California.